SALL4 degrader / Novartis - LARVOL DELTA

Identification of a small molecule degrader targeting SALL4 oncogene (AACR 2026) - "Gene expression profiling via RNA-sequencing identified a shared drug and SALL4B knock down gene signature in hepatocellular carcinoma (HCC) cells, including pathways involved in DNA damage response and DNA replication. Our findings highlight the importance of understanding drug action and oncogenesis at the isoform level to develop more effective cancer therapeutics."

Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • SALL4